Not provided
Not provided
Not provided
Not provided
Not provided
PI left institution
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hypothesis is that tear substitutions cause blur after they are instilled. The investigators will use aberrometry as a measurement over time after a tear formulation is used and try to determine if there are any measurable change in higher order aberrations between different tear formulations and how long it takes to return to pre-instillation measurements thus providing information on duration of the tear drop. 4 commercially available "dry eye" artificial tears formulations will be used and preservative saline will act as a control. The study will be conducted on subjects that do not have clinical evidence of dry eye syndrome to focus the data on the blur effects of the tear substitutions.
Once consent is obtained the subject will choose from available time slots. Each subject will come to the UIHC Department of Ophthalmology at designated times for approximately one hour on five different days, for a total time commitment of approximately 5 hours. Each subject will receive the same 4 artificial tear substitutes and saline, one different drop each day. One of the four tear substitutes (brands: Systane, Systane Ultra, Optive, and Refresh) will be tested on each of the days. One drop will be used each day and the protocol of each day will be the same, the only factor changing from day to day is the drop that is being evaluated. On each study day, the subject will have a pre-instillation measurement of their higher order aberrometry of each eye. One drop of the designated drop will be placed into each of the eyes. Subsequent aberrometry measurements of each eye will be taken at immediately post-instillation, 5 minutes, 30 minutes and 60 minutes post instillation. The same protocol will be followed with a saline drop and thus each patient will act as a control.
There is no long-term follow-up.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Placebo Comparator | Preservative Free Saline |
|
| 2 | Active Comparator | Optive (TM) |
|
| 3 | Active Comparator | Refresh Moderate/Severe (TM) |
|
| 4 | Active Comparator | Systane (TM) |
|
| 5 | Active Comparator | Systane Ultra (TM) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Preservative Free Saline | Other | One drop will be instilled into each eye once |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of a subject's higher order aberrations over time is the primary outcome measure | pre drop instillation, 1, 5, 15, 30, and 60 minutes post instillation |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gina M Rogers, MD | University of Iowa Department of Ophthalmology and Visual Sciences | Principal Investigator |
| Christine Sindt, OD | niversity of Iowa Department of Ophthalmology and Visual Sciences | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Iowa Department of Ophthalmology and Visual Sciences | Iowa City | Iowa | 52242 | United States |
Not provided
| ID | Term |
|---|---|
| D015352 | Dry Eye Syndromes |
| ID | Term |
|---|---|
| D007766 | Lacrimal Apparatus Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Optive |
| Other |
One drop will be instilled into each eye once |
|
| Refresh Moderate/Severe | Other | One drop will be instilled into each eye once |
|
| Systane | Other | One drop will be instilled into each eye once |
|
| Systane Ultra | Other | One drop will be instilled into each eye once |
|